High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  1993-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V81.11.3091.BLOODJOURNAL81113091PMID 7684624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.

  1992cited by this paper
• bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.

  1992cited by this paper
• BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

  1991cited by this paper
• Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms.

  1991cited by this paper
• Bcl-2 maintains B cell memory

  1991cited by this paper
• Germinal center cells express bcl‐2 protein after activation by signals which prevent their entry into apoptosis

  1991cited by this paper
• Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.

  1990cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

  1990cited by this paper
• Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell.

  1989cited by this paper
• Bullous pemphigoid and cicatricial pemphigoid: immunoblotting detection of involved autoantigens.

  1989cited by this paper
• Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy

  1989cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Variable differentiation patterns of acute myelogenous leukaemia blasts in liquid suspension cultures

  1987cited by this paper
• Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.

  1987cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper
• Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

  1984cited by this paper
• Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.

  1968cited by this paper

• Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope.

  2026cites this paper
• Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

  2026cites this paper
• Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era

  2025cites this paper
• A CEBPB/IL-1β/TNF-α Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.

  2025cites this paper
• Decreased expression of BCL2 protein on the diagnostic bone marrow T cells in adult acute myeloid leukemia

  2025cites this paper
• Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities

  2025cites this paper
• The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

  2025cites this paper
• Complementing therapeutic strategies for acute myeloid leukemia: Signaling pathways and targets of traditional Chinese medicine.

  2025cites this paper
• Increased anti‐apoptotic (Bcl‐2+) and decreased proliferative (Ki‐67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML: The potential diagnostic impact of the Bcl‐2:Ki‐67 ratio

  2025cites this paper
• miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting

  2025cites this paper
• Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease

  2025cites this paper
• Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia

  2025cites this paper
• Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

  2025cites this paper
• Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

  2025cites this paper
• Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia

  2025cites this paper
• Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10

  2025cites this paper
• Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia

  2025cites this paper
• Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.

  2024cites this paper
• Venetoclax Resistance in Acute Myeloid Leukemia

  2024cites this paper
• Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance

  2024cites this paper
• Fix low dose venetoclax‐azacitidine treatment of unfit acute myeloid leukemia patients

  2024cites this paper
• MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.

  2024cites this paper
• Biomarker-directed therapy in multiple myeloma

  2024cites this paper
• CRISPR screens in mechanism and target discovery for AML

  2024cites this paper
• Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia

  2024cites this paper
• Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax

  2024cites this paper
• GRK2 Protein Mediates the ANRIL, a lncRNA, to Affect the Proliferation and Apoptosis of Kasumi-1 Cells.

  2024cites this paper
• Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches

  2024cites this paper
• Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multi-center Cohort Study.

  2024cites this paper
• Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis

  2023cites this paper
• Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products via the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic Implications

  2023cites this paper
• Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

  2023cites this paper
• Acute myeloid leukemia in elderly patients: New targets, new therapies

  2023cites this paper
• Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

  2023cites this paper
• Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation

  2023cites this paper
• SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.

  2023cites this paper
• Mechanisms of alkaliptosis

  2023cites this paper
• Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML

  2023cites this paper
• Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis

  2023cites this paper
• BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.

  2023cites this paper
• A comparative safety review of targeted therapies for acute myeloid leukemia

  2023cites this paper
• HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

  2023cites this paper
• Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.

  2023cites this paper
• Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia

  2023cites this paper
• Microenvironment in Acute Myeloid Leukemia: focus on senescence mechanisms, therapeutic interactions and future directions.

  2023cites this paper
• CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo

  2023cites this paper
• Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.

  2023cites this paper
• Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis

  2023cites this paper
• Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse

  2023cites this paper
• Novel Therapies in Myelodysplastic Syndrome

  2023cites this paper
• An Overview of Targeted Therapies in Acute Myeloid Leukemia

  2023cites this paper
• Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients

  2023cites this paper
• Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling

  2023cites this paper
• High Expression of DC-STAMP Gene Predicts Adverse Outcomes in AML

  2022cites this paper
• 维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效：单中心数据

  2022cites this paper
• Venetoclax resistance: mechanistic insights and future strategies

  2022cites this paper
• Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

  2022cites this paper
• Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé

  2022cites this paper
• Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

  2022cites this paper
• New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

  2022cites this paper
• Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia

  2022cites this paper
• A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.

  2022cites this paper
• Targeting Apoptosis in AML: Where Do We Stand?

  2022cites this paper
• Early response evaluation by single cell signaling profiling in acute myeloid leukemia

  2022cites this paper
• Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model

  2022cites this paper
• Developments and challenges of FLT3 inhibitors in acute myeloid leukemia

  2022cites this paper
• BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.

  2022cites this paper
• Targeted therapy in NPM1-mutated AML: Knowns and unknowns

  2022cites this paper
• Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

  2022cites this paper
• Can the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following Induction Therapy?

  2022cites this paper
• mir210 and BCL2 Expressions in Patients with Acute Myeloid Leukemia

  2022cites this paper
• Updates on the Management of Acute Myeloid Leukemia

  2022cites this paper
• Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.

  2022cites this paper
• An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia

  2022cites this paper
• Importance of targeted therapies in acute myeloid leukemia

  2021cites this paper
• Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance

  2021cites this paper
• Carotenoids as Anticancer Agents

  2021cites this paper
• Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

  2021cites this paper
• Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?

  2021cites this paper
• FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

  2021cites this paper
• Long non-coding RNAs in cancer stem cells

  2021cites this paper
• Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia

  2021cites this paper
• Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia

  2021cites this paper
• YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.

  2021cites this paper
• Emerging agents and regimens for AML

  2021cites this paper
• Knockdown of Annexin A1 induces apoptosis, causing G2/M arrest and facilitating phagocytosis activity in human leukemia cell lines

  2021cites this paper
• Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer

  2021cites this paper
• BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies

  2021cites this paper
• Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia

  2021cites this paper
• Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia

  2021cites this paper
• Apoptotic Pathway

  2021cites this paper
• The beginning of a new therapeutic era in acute myeloid leukemia

  2021cites this paper
• SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.

  2021cites this paper
• Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

  2021cites this paper
• A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia

  2021cites this paper
• BH3 Mimetics in Hematologic Malignancies

  2021cites this paper
• Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center

  2021cites this paper
• Novel Insights into YB-1 Signaling and Cell Death Decisions

  2021cites this paper
• Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

  2021cites this paper
• Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

  2021cites this paper